Brain-Derived Neurotrophic Factor as a Treatment Option for Retinal Degeneration. Adv Exp Med Biol 2018;1074:465-471
Date
05/04/2018Pubmed ID
29721977DOI
10.1007/978-3-319-75402-4_57Scopus ID
2-s2.0-85046643012 (requires institutional sign-in at Scopus site) 18 CitationsAbstract
This review discusses the therapeutic potential of brain-derived neurotrophic factor (BDNF) for retinal degeneration. BDNF, nerve growth factor (NGF), neurotrophin 3 (NT-3) and NT-4/NT-5 belong to the neurotrophin family. These neuronal modulators activate a common receptor and a specific tropomyosin-related kinase (Trk) receptor. BDNF was identified as a photoreceptor protectant in models of retinal degeneration as early as 1992. However, development of effective therapeutics that exploit this pathway has been difficult due to challenges in sustaining therapeutic levels in the retina.
Author List
Daly C, Ward R, Reynolds AL, Galvin O, Collery RF, Kennedy BNAuthor
Ross F. Collery PhD Associate Professor in the Ophthalmology and Visual Sciences department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsBrain-Derived Neurotrophic Factor
Cell Survival
Dependovirus
Disease Models, Animal
Drug Evaluation, Preclinical
Genetic Therapy
Genetic Vectors
Humans
Mice
Neuroprotective Agents
Photoreceptor Cells, Vertebrate
Rats
Recombinant Proteins
Retinal Degeneration
